1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ocuphire Pharma Inc (OCUP)
  7. News

OCUP

Ocuphire Pharma News

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Ocuphire Pharma Inc OCUP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.47% 2.15 18:06:03
Open Price Low Price High Price Close Price Prev Close
2.14 2.09 2.17 2.15 2.14
more quote information »

Recent News

Date Time Source Heading
5/27/202212:49IHNWFeaturedFansUnite Reports First Quarter Fiscal 2022 Financial Results
5/23/202216:59EDGARStatement of Changes in Beneficial Ownership (4)
5/22/202204:30TRMNH.C. Wainwright Thinks Ocuphire Pharma’s Stock is Going to..
5/19/202207:44EDGARCurrent Report Filing (8-k)
5/17/202216:38EDGARStatement of Ownership (sc 13g)
5/13/202209:02EDGARQuarterly Report (10-q)
5/13/202208:15EDGARCurrent Report Filing (8-k)
5/02/202204:45TRMNH.C. Wainwright Thinks Ocuphire Pharma’s Stock is Going to..
4/28/202207:18EDGARCurrent Report Filing (8-k)
4/27/202209:08EDGARProxy Statement (definitive) (def 14a)
4/05/202216:18EDGARSecurities Registration: Employee Benefit Plan (s-8)
4/05/202209:17EDGARStatement of Changes in Beneficial Ownership (4)
4/05/202209:12EDGARStatement of Changes in Beneficial Ownership (4)
3/29/202208:27EDGARCurrent Report Filing (8-k)
3/29/202208:18SEEKOcuphire eye drop Nyxol for reversing pupil dilation meets..
3/25/202206:16TRMNOcuphire Pharma (OCUP) Gets a Buy Rating from H.C...
3/24/202209:02SEEKOcuphire Pharma GAAP EPS of -$0.35 misses by $0.09
3/24/202208:18EDGARCurrent Report Filing (8-k)
3/08/202210:49SEEKOcuphire completes enrollment in pediatric patients study of..
2/14/202216:20EDGARAmended Statement of Ownership (sc 13g/a)
2/14/202209:53EDGARAmended Statement of Ownership (sc 13g/a)
2/14/202209:17EDGARAnnual Statement of Changes in Beneficial Ownership (5)
2/08/202211:59SEEKOcuphire completes registrational study for lead asset ahead..
2/01/202216:23EDGARStatement of Changes in Beneficial Ownership (4)
1/31/202209:55EDGARCurrent Report Filing (8-k)
1/31/202207:00SEEKOcuphire Pharma eyes launch of mydriasis therapy in 2023
1/31/202206:17EDGARCurrent Report Filing (8-k)
1/19/202214:45TRMNOcuphire Pharma: A High-Risk, High-Reward Stock
1/18/202211:17EDGARAmended Statement of Ownership (sc 13g/a)
1/05/202216:02EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202216:02EDGARStatement of Changes in Beneficial Ownership (4)
1/05/202207:06EDGARCurrent Report Filing (8-k)
11/24/202113:01SEEKOcuphire up 36% as H.C. Wainwright initiates with a buy;..
11/24/202106:16TRMNAnalysts Offer Insights on Healthcare Companies: Palatin..
11/23/202109:09SEEKEnrollment underway in Ocuphire's second Phase 3 Nyxol trial..
11/22/202116:02EDGARStatement of Changes in Beneficial Ownership (4)
11/15/202117:46EDGARCurrent Report Filing (8-k)
11/12/202108:32EDGARQuarterly Report (10-q)
11/12/202107:39SEEKOcuphire Pharma EPS beats by $0.09
10/04/202116:02EDGARStatement of Changes in Beneficial Ownership (4)
9/20/202109:54TRMNOcuphire Stock: Worth Keeping an Eye on
9/15/202108:02EDGARStatement of Changes in Beneficial Ownership (4)
9/03/202117:00GLOBEOcuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq..
9/03/202116:03EDGARStatement of Changes in Beneficial Ownership (4)
8/12/202116:55EDGARQuarterly Report (10-q)
8/12/202107:45SEEKOcuphire Pharma EPS misses by $0.08
8/12/202107:32EDGARCurrent Report Filing (8-k)
7/02/202116:02EDGARStatement of Changes in Beneficial Ownership (4)
7/02/202116:02EDGARStatement of Changes in Beneficial Ownership (4)
6/30/202107:37SEEKOcuphire stock rockets 71% after Phase 2 VEGA-1 trial in..
6/20/202103:27TRMNOcuphire Pharma: Keep Your Eye on this Stock


Your Recent History
NASDAQ
OCUP
Ocuphire P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.